58 results
8-K
EX-99.1
NRBO
NeuroBo Pharmaceuticals Inc
9 May 24
NeuroBo Pharmaceuticals Reports First Quarter 2024 Financial Results
8:05am
on a timely basis; NeuroBo’s ability to recruit subjects for its clinical trials; whether NeuroBo receives results from NeuroBo’s clinical trials
8-K
EX-99.1
NRBO
NeuroBo Pharmaceuticals Inc
30 Apr 24
Other Events
8:30am
clinical trials on a timely basis; our ability to recruit subjects for its clinical trials; whether NeuroBo receives results from NeuroBo's clinical
8-K
EX-99.1
NRBO
NeuroBo Pharmaceuticals Inc
17 Apr 24
NeuroBo Pharmaceuticals Doses First Patient in Its Phase 1 Clinical Trial Evaluating
8:30am
; NeuroBo’s ability to initiate and complete clinical trials on a timely basis; our ability to recruit subjects for its clinical trials; whether
8-K
EX-99.1
al98 ouy4
16 Apr 24
Other Events
4:30pm
8-K
EX-99.1
ryiyesh 9jevy4eb
1 Apr 24
NeuroBo Pharmaceuticals Completes Enrollment of Part 1 of Its Phase 2a Clinical Trial Evaluating DA-1241 for the Treatment of MASH
8:30am
8-K
EX-99.1
6to9jo3 tlpm91
28 Mar 24
NeuroBo Pharmaceuticals Reports Year End 2023 Financial Results and Provides Corporate Update
8:01am
8-K
EX-99.1
qsvo djjmot189
13 Mar 24
Blinded Safety Review Completed for the First 6 Months of the Phase 2a Clinical Trial Conduct; Recommending Trial Continue Without Modification
8:30am
8-K
EX-99.1
no4t9ff5y14zit
4 Mar 24
NeuroBo Pharmaceuticals Appoints Seasoned Life Science Executive
7:30am
8-K
EX-99.1
cjt8vi9d 9ev5np34prz
29 Feb 24
NeuroBo Pharmaceuticals Receives First Site IRB Approval for Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity
8:30am
8-K
EX-99.1
tlfff2mdo05c8
14 Feb 24
Other Events
8:52am
8-K
EX-99.1
vyrkzle kfb
1 Feb 24
NeuroBo Pharmaceuticals Announces FDA Clearance of IND for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
8:30am
8-K
EX-99.1
thdygtd9s6elc4l6k
18 Jan 24
Full Data Readout Expected in the Second Half of 2024
8:30am
8-K
EX-99.1
rfba0fe1 drqbyz60u
9 Jan 24
Other Events
8:45am
8-K
EX-99.1
v24 cxy426
28 Dec 23
NeuroBo Pharmaceuticals Submits IND Application to the FDA for a Phase 1 Clinical Trial of DA-1726 for the Treatment of Obesity
9:00am
8-K
EX-99.1
x829t
19 Dec 23
NeuroBo Pharmaceuticals Announces 1-for-8 Reverse Stock Split
9:03am
8-K
EX-99.1
q05z3
7 Dec 23
Regulation FD Disclosure
9:20am